We identified 42 germline variants of interest in 58 of 9089 TCGA participants (0.6%) across all cancer entities, including 8 variants present in the NCI’s TBD cohort (4 loss of function and 4 missense affecting either CTC1, RTEL1, TERT, or WRAP53) (eTable 5 and eTable 15 in Supplement 1). This evidence concerns the gene TERT and cancer.